Electrochemiluminescence Assay
Electrochemiluminescence Assay - Related Videos
06:09
Detection of Human Islet Autoantibodies Using an Electrochemiluminescence Assay
0 Views •
2025
This video showcases the electrochemiluminescence detection of islet autoantibodies in human serum. The antibodies in the serum bridge the ruthenium-conjugated antigen to the biotinylated capture antigen, forming complexes that are detected by electrochemiluminescence measurements.
06:25
Electrochemiluminescence Assay for Quantification of Target Protein Levels in Brain Lysate
0 Views •
2025
In this video, we demonstrate the electrochemiluminescence immunoassay for the quantitation of target protein levels in different samples. This assay is based on the luminescence produced in the electrochemical reaction. The intensity of light emitted is proportional to the quantity of the target protein in the sample.
09:15
Electrochemiluminescence Assays for Human Islet Autoantibodies
0 Views •
Cited by 8 •
2018
Here, we presented the methods to detect human islet autoantibodies using electrochemiluminescence (ECL) assays. The protocol, used to predict type 1 diabetes, can be expanded upon to detect autoantibodies for other autoimmune diseases.
07:44
An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
0 Views •
Cited by 2 •
2020
The electrochemiluminescence immunoassay (ECLIA) is a novel approach for quantitative detection of endogenous and exogenously applied MeCP2 protein variants, which produces highly quantitative, accurate and reproducible measurements with low intra- and inter-assay error over a wide working range. Here, the protocol for the MeCP2-ECLIA in a 96-well format is described.
06:50
A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
0 Views •
Cited by 3 •
2020
We model a simple multiplexed ECL assay that combines 7 autoantibody assays together. The assay is capable of screening for T1D and multiple other autoimmune diseases, simultaneously, including celiac disease, autoimmune thyroid disease, and autoimmune polyglandular syndrome 1.
FAQs
At the detection stage, an applied electrical potential stimulates the label attached to the detection reagent, causing light emission. The instrument measures that light, and its intensity is used to quantify the target in the sample. This coupling of electrochemical stimulation and optical readout supports sensitive measurement across a broad concentration range.
Antibody arrangement determines which molecular interaction produces the signal. One antibody captures the antigen or antibody of interest, and a labeled detection reagent binds to the formed complex. Because the measured light is associated with this captured-and-detected complex, the assay can focus measurement on a specified immune or infection-related target.
Multiplexing potential allows an assay format to support measurement of more than one analyte, making it useful when immune responses contain several relevant biomarkers. Along with sensitivity and broad-range measurement, this capability helps investigators examine cytokines, antibodies, pathogen antigens, and other markers within biological samples rather than studying only one signal.
Electrochemical stimulation acts as the controlled readout trigger: it causes the label on the detection reagent to emit light after the target-associated complex has formed. The measured intensity then connects antibody-based molecular recognition to quantitative analysis. This sequence separates target capture from signal generation while preserving a relationship between target amount and light output.
A typical workflow begins with a biological sample containing the target. An antibody captures the antigen or antibody of interest, a labeled detection reagent binds the resulting complex, and an applied electrical potential stimulates light emission. Measuring the emitted light provides the signal used to quantify the target, completing the analytical readout.
In immunology and infection studies, measured targets can include cytokines, antibodies, pathogen antigens, and other infection-related biomarkers. Selecting among these target classes lets investigators examine immune responses, detect disease-associated molecules, or characterize signals linked to infection. The same analytical principle therefore supports questions about both host immunity and the presence of pathogens.
Evaluation of therapeutic interventions is another important application. By measuring infection-related biomarkers, cytokines, or antibodies, investigators can assess biological signals associated with an intervention. The assay is therefore useful when a study needs quantitative molecular measurements to compare immune or infection-related states during research on treatment effects.